Journal article
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Movement disorders, Vol.36(8), pp.1972-1978
08/2021
DOI: 10.1002/mds.28608
PMCID: PMC8453505
PMID: 33942926
Abstract
Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD).
The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis.
Absolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies.
Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment.
HVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Details
- Title: Subtitle
- Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
- Creators
- Thomas Kremer - Roche Pharmaceutical Research and Early Development, NRD Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandKirsten I Taylor - Faculty of Psychology, University of Basel, Basel, SwitzerlandJuliane Siebourg-Polster - Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandThomas Gerken - Metanomics Health GmbH, Berlin, GermanyAndreas Staempfli - Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandChristian Czech - Roche Pharmaceutical Research and Early Development, NRD Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandJuergen Dukart - Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, GermanyDouglas Galasko - Department of Neurosciences, University of California, San Diego, San Diego, California, USATatiana Foroud - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USALana M Chahine - Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USAChristopher S Coffey - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USATanya Simuni - Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USADaniel Weintraub - Department of Neurology Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAJohn Seibyl - Institute for Neurodegenerative Disorders, New Haven, Connecticut, USAKathleen L Poston - Department of Neurology & Neurological Sciences, School of Medicine, Stanford University, Stanford, California, USAArthur W Toga - Laboratory of Neuro Imaging, University of Southern California (USC) Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of University of Southern California, Los Angeles, California, USACaroline M Tanner - Parkinson's Disease Research Education and Clinical Center, San Francisco Veterans Affairs Health Care System, San Diego, California, USAKenneth Marek - The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USASamantha J Hutten - The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USASebastian Dziadek - Roche Pharmaceutical Research and Early Development, NRD Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandClaudia Trenkwalder - Paracelsus-Elena-Klinik, Kassel, GermanyGennaro Pagano - Roche Pharmaceutical Research and Early Development, NRD Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, SwitzerlandBrit Mollenhauer - Department of Neurology, University Medical Center Göttingen, Göttingen, Germany
- Resource Type
- Journal article
- Publication Details
- Movement disorders, Vol.36(8), pp.1972-1978
- DOI
- 10.1002/mds.28608
- PMID
- 33942926
- PMCID
- PMC8453505
- NLM abbreviation
- Mov Disord
- ISSN
- 0885-3185
- eISSN
- 1531-8257
- Grant note
- P41 EB015922 / NIBIB NIH HHS
- Language
- English
- Date published
- 08/2021
- Academic Unit
- Biostatistics
- Record Identifier
- 9984214667702771
Metrics
16 Record Views